These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 30375388)

  • 1. Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition.
    LaRochelle JR; Fodor M; Vemulapalli V; Mohseni M; Wang P; Stams T; LaMarche MJ; Chopra R; Acker MG; Blacklow SC
    Nat Commun; 2018 Oct; 9(1):4508. PubMed ID: 30375388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2.
    Pádua RAP; Sun Y; Marko I; Pitsawong W; Stiller JB; Otten R; Kern D
    Nat Commun; 2018 Oct; 9(1):4507. PubMed ID: 30375376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
    Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
    Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canine histiocytic sarcoma cell lines with SHP2 p.Glu76Gln or p.Glu76Ala mutations are sensitive to allosteric SHP2 inhibitor SHP099.
    Tani H; Kurita S; Miyamoto R; Ochiai K; Tamura K; Bonkobara M
    Vet Comp Oncol; 2020 Jun; 18(2):161-168. PubMed ID: 31339650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Allosteric Inhibition of SHP2 Phosphatase.
    Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
    ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel partially open state of SHP2 points to a "multiple gear" regulation mechanism.
    Tao Y; Xie J; Zhong Q; Wang Y; Zhang S; Luo F; Wen F; Xie J; Zhao J; Sun X; Long H; Ma J; Zhang Q; Long J; Fang X; Lu Y; Li D; Li M; Zhu J; Sun B; Li G; Diao J; Liu C
    J Biol Chem; 2021; 296():100538. PubMed ID: 33722610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the dynamic mechanism of allosteric drug SHP099 inhibiting SHP2
    Du S; Lu XH; Li WY; Li LP; Ma YC; Zhou L; Wu JW; Ma Y; Wang RL
    Mol Divers; 2021 Aug; 25(3):1873-1887. PubMed ID: 33392964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
    Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
    J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.
    Pfeiffer A; Franciosa G; Locard-Paulet M; Piga I; Reckzeh K; Vemulapalli V; Blacklow SC; Theilgaard-Mönch K; Jensen LJ; Olsen JV
    Cancer Res; 2022 Jun; 82(11):2141-2155. PubMed ID: 35311954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
    Jin WY; Ma Y; Li WY; Li HL; Wang RL
    Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective inhibition of leukemia-associated SHP2
    Sun X; Ren Y; Gunawan S; Teng P; Chen Z; Lawrence HR; Cai J; Lawrence NJ; Wu J
    Leukemia; 2018 May; 32(5):1246-1249. PubMed ID: 29568093
    [No Abstract]   [Full Text] [Related]  

  • 12. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
    Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
    Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel PROTACs for degradation of SHP2 protein.
    Zheng M; Liu Y; Wu C; Yang K; Wang Q; Zhou Y; Chen L; Li H
    Bioorg Chem; 2021 May; 110():104788. PubMed ID: 33706076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
    Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
    J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
    Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
    J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small Molecule Inhibitor that Stabilizes the Autoinhibited Conformation of the Oncogenic Tyrosine Phosphatase SHP2.
    Wu X; Xu G; Li X; Xu W; Li Q; Liu W; Kirby KA; Loh ML; Li J; Sarafianos SG; Qu CK
    J Med Chem; 2019 Feb; 62(3):1125-1137. PubMed ID: 30457860
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).
    Liu W; Yu B; Xu G; Xu WR; Loh ML; Tang LD; Qu CK
    J Med Chem; 2013 Sep; 56(18):7212-21. PubMed ID: 23957426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain-of-function mutations in the gene encoding the tyrosine phosphatase SHP2 induce hydrocephalus in a catalytically dependent manner.
    Zheng H; Yu WM; Waclaw RR; Kontaridis MI; Neel BG; Qu CK
    Sci Signal; 2018 Mar; 11(522):. PubMed ID: 29559584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).
    Wu J; Zhang H; Zhao G; Wang R
    Curr Med Chem; 2021; 28(19):3825-3842. PubMed ID: 32988341
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Valencia-Sama I; Ladumor Y; Kee L; Adderley T; Christopher G; Robinson CM; Kano Y; Ohh M; Irwin MS
    Cancer Res; 2020 Aug; 80(16):3413-3423. PubMed ID: 32586982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.